Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01247571 · OUTCOME

Number of Patients With Grade 3 or Higher Adverse Events

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Every cycle while on treatment

What was measured

Grade 3 or higher adverse events were graded by CTCAE v4.

Analysis population: Eligible and Treated Patients

Groups in this outcome

Pazopanib

Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib19

Reported measurements

Anemia
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib3Not reportedNot reportedNot reportedNot reported
Hypertension
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib3Not reportedNot reportedNot reportedNot reported
Abdominal pain
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib2Not reportedNot reportedNot reportedNot reported
Hyperglycemia
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib2Not reportedNot reportedNot reportedNot reported
Hypoglycemia
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib2Not reportedNot reportedNot reportedNot reported
Alanine aminotransferase increased
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Ascites
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Aspartate aminotransferase increased
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Creatinine increasead
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Death NOS
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Dehydration
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Diarrhea
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Dyspnea
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Fatigue
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Headache
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Hypocalcemia
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Hyponatremia
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Memory impairment
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Nausea
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Proctitis
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Rectal hemorrhage
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Sepsis
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Vomiting
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Pazopanib1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Anemia
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Hypertension
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Abdominal pain
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Hyperglycemia
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Hypoglycemia
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Alanine aminotransferase increased
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Ascites
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Aspartate aminotransferase increased
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Creatinine increasead
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Death NOS
  11. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Dehydration
  12. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Diarrhea
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
Grade 3 or higher adverse events were graded by CTCAE v4.
groups
  1. description
    Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)
    id
    OG000
    title
    Pazopanib
param Type
NUMBER
population Description
Eligible and Treated Patients
reporting Status
POSTED
time Frame
Every cycle while on treatment
title
Number of Patients With Grade 3 or Higher Adverse Events
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice